Get the Stockscreener App
3.22
11.81%
0.34
After Hours:
3.25
0.03
+0.93%
Sonnet Biotherapeutics Holdings Inc stock is traded at $3.22, with a volume of 751.19K.
It is up +11.81% in the last 24 hours and down -27.96% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$2.88
Open:
$2.99
24h Volume:
751.19K
Relative Volume:
0.21
Market Cap:
$10.19M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
-0.2878
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
+14.59%
1M Performance:
-27.96%
6M Performance:
+102.52%
1Y Performance:
-45.62%
1-Day Range:
$2.75
$3.36
1-Week Range:
$2.48
$3.36
52-Week Range:
$1.08
$19.30
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Compare SONN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
3.22 | 18.67M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here? - inkl
Sonnet BioTherapeutics Expands Clinical Study of SON-1010 in Combination with Atezolizumab for Advanced Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Sonnet BioTherapeutics Expands Clinical Evaluation of - GlobeNewswire
Cancer Drug Shows 66% Response Rate in Ovarian Cancer Trial: Sonnet BioTherapeutics Advances to Higher Dose - Stock Titan
Live Chart Scan Detects Wedge Pattern in Sonnet BioTherapeutics Holdings Inc.Swing Trade Entry With Volume Triggers Released - beatles.ru
Is Sonnet BioTherapeutics Holdings Inc. stock overvalued or undervaluedRecord-breaking capital gains - Jammu Links News
What is the dividend policy of Sonnet BioTherapeutics Holdings Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Why is Sonnet BioTherapeutics Holdings Inc. stock attracting strong analyst attentionCapitalize on proven investment strategies - Jammu Links News
How strong is Sonnet BioTherapeutics Holdings Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
What analysts say about Sonnet BioTherapeutics Holdings Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
What are the latest earnings results for Sonnet BioTherapeutics Holdings Inc.Fastest return on investment - Jammu Links News
What institutional investors are buying Sonnet BioTherapeutics Holdings Inc. stockExpert guidance for superior capital growth - Jammu Links News
What is the risk reward ratio of investing in Sonnet BioTherapeutics Holdings Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
What drives Sonnet BioTherapeutics Holdings Inc. stock priceStay ahead with daily market updates - Jammu Links News
What catalysts could drive Sonnet BioTherapeutics Holdings Inc. stock higher in 2025Dynamic profit expansion - Jammu Links News
Is it the right time to buy Sonnet BioTherapeutics Holdings Inc. stockHigh-velocity gains - Jammu Links News
Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao - TipRanks
Sonnet BioTherapeutics enters employment agreement with interim CEO Raghu Rao - Investing.com Australia
Is this a good reentry point in Sonnet BioTherapeutics Holdings Inc.Earnings Play Trade Plan With Alerts Shared - metal.it
Is Sonnet BioTherapeutics Holdings Inc. a growth stock or a value stockBest Dividend Insights For Fast Growth - Jammu Links News
Why Sonnet BioTherapeutics Holdings Inc. stock attracts strong analyst attentionSmart Money Tracking Signal Generator Activated - beatles.ru
Real time social sentiment graph for Sonnet BioTherapeutics Holdings Inc.Daily Smart Money Movement Monitor Activated - metal.it
Published on: 2025-07-30 03:59:14 - metal.it
Published on: 2025-07-29 23:38:09 - metal.it
Published on: 2025-07-29 20:04:07 - metal.it
Pattern Scan Adds Sonnet BioTherapeutics Holdings Inc. to WatchlistWealth Building Stock Market Ideas Based on Momentum - beatles.ru
Analyzing net buyer seller activity in Sonnet BioTherapeutics Holdings Inc.Insider Strategy for High Conviction Picks - Newser
Sonnet BioTherapeutics Holdings Inc. Company Revenue and Profit Trends: A Deep DiveWeekly Double Return List - metal.it
How Interest Rate Changes Impact Sonnet BioTherapeutics Holdings Inc. Stock PerformanceFree Access to Community - Newser
Top Risks to Consider Before Buying Sonnet BioTherapeutics Holdings Inc. StockFree Deep Market Trend Analysis - Newser
Sonnet BioTherapeutics Regains Nasdaq Compliance After Fundraising - The Globe and Mail
Sonnet BioTherapeutics Holdings Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - PrintWeekIndia
Is Sonnet BioTherapeutics Holdings Inc. a good long term investmentFree Capital Efficiency Planning - PrintWeekIndia
How Sonnet BioTherapeutics Holdings Inc. stock performs during market volatilityFree Market Analysis Group - Newser
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - Yahoo.co
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):